{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:48:31Z","timestamp":1790790511008,"version":"4.1.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","heartfailure.onlinejacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.jchf.2018.01.009","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T00:03:37Z","timestamp":1520467417000},"page":"633-639","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":154,"title":["Obesity-Related Heart Failure With a Preserved Ejection Fraction"],"prefix":"10.1016","volume":"6","author":[{"given":"Milton","family":"Packer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalane W.","family":"Kitzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2018.01.009_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","article-title":"Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap","volume":"134","author":"Shah","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2018.01.009_bib2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2018.01.009_bib3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1161\/CIRCULATIONAHA.117.028365","article-title":"Obese heart failure with preserved ejection fraction phenotype: from pariah to central player","volume":"136","author":"Kitzman","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2018.01.009_bib4","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jacc.2016.05.019","article-title":"The HFpEF obesity phenotype: the elephant in the room","volume":"68","author":"Kitzman","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2018.01.009_bib5","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa020245","article-title":"Obesity and the risk of heart failure","volume":"347","author":"Kenchaiah","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2018.01.009_bib6","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0002-9343(99)00126-6","article-title":"Risk factors for heart failure in the elderly: a prospective community-based study","volume":"106","author":"Chen","year":"1999","journal-title":"Am J Med"},{"key":"10.1016\/j.jchf.2018.01.009_bib7","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3389\/fendo.2017.00160","article-title":"Targeting obesity and diabetes to treat heart failure with preserved ejection fraction","volume":"8","author":"Altara","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jchf.2018.01.009_bib8","first-page":"S254","article-title":"Mechanisms of hypertension in obesity","volume":"22","author":"Dornfeld","year":"1987","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.jchf.2018.01.009_bib9","doi-asserted-by":"crossref","first-page":"F639","DOI":"10.1152\/ajprenal.2001.281.4.F639","article-title":"Increased renal Na-K-ATPase, NCC, and beta-ENaC abundance in obese Zucker rats","volume":"281","author":"Bickel","year":"2001","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jchf.2018.01.009_bib10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/cphy.c160014","article-title":"Contribution of maladaptive adipose tissue expansion to development of cardiovascular disease","volume":"7","author":"Jia","year":"2016","journal-title":"Compr Physiol"},{"key":"10.1016\/j.jchf.2018.01.009_bib11","doi-asserted-by":"crossref","first-page":"R387","DOI":"10.1152\/ajpregu.00235.2016","article-title":"Cellular mechanisms underlying obesity-induced arterial stiffness","volume":"314","author":"Aroor","year":"2018","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.jchf.2018.01.009_bib12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cardfail.2015.11.004","article-title":"Vascular dysfunction in heart failure with preserved ejection fraction","volume":"22","author":"Kitzman","year":"2016","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jchf.2018.01.009_bib13","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1161\/HYPERTENSIONAHA.111.00163","article-title":"Carotid arterial stiffness and its relationship to exercise intolerance in older patients with heart failure and preserved ejection fraction","volume":"61","author":"Kitzman","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.jchf.2018.01.009_bib14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1532-429X-11-48","article-title":"Reduced peripheral arterial blood flow with preserved cardiac output during submaximal bicycle exercise in elderly heart failure","volume":"11","author":"Puntawangkoon","year":"2009","journal-title":"J\u00a0Cardiovasc Magn Reson"},{"key":"10.1016\/j.jchf.2018.01.009_bib15","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1161\/CIRCULATIONAHA.114.009625","article-title":"Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction","volume":"131","author":"Mohammed","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2018.01.009_bib16","first-page":"312","article-title":"Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction","volume":"4","author":"Franssen","year":"2016","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2018.01.009_bib17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A\u00a0novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2018.01.009_bib18","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ejhf.497","article-title":"Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation","volume":"18","author":"Ter Maaten","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2018.01.009_bib19","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s10741-017-9644-1","article-title":"Epicardial adipose tissue as a metabolic transducer: role in heart failure and coronary artery disease","volume":"22","author":"Patel","year":"2017","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jchf.2018.01.009_bib20","doi-asserted-by":"crossref","first-page":"H883","DOI":"10.1152\/ajpheart.00332.2010","article-title":"Decreased left ventricular distensibility in response to postural change in older patients with heart failure and preserved ejection fraction","volume":"299","author":"John","year":"2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jchf.2018.01.009_bib21","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jacc.2006.10.061","article-title":"Ventricular structure and function in hypertensive participants with heart failure and a normal ejection fraction: the Cardiovascular Health Study","volume":"49","author":"Maurer","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2018.01.009_bib22","doi-asserted-by":"crossref","first-page":"e004281","DOI":"10.1161\/CIRCHEARTFAILURE.117.004281","article-title":"Making the case for skeletal muscle myopathy and its contribution to exercise intolerance in heart failure with preserved ejection fraction","volume":"10","author":"Kitzman","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2018.01.009_bib23","first-page":"636","article-title":"Skeletal muscle mitochondrial content, oxidative capacity, and Mfn2 expression are reduced in older patients with heart failure and preserved ejection fraction and are related to exercise intolerance","volume":"4","author":"Molina","year":"2016","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2018.01.009_bib24","doi-asserted-by":"crossref","first-page":"H1364","DOI":"10.1152\/ajpheart.00004.2014","article-title":"Skeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction","volume":"306","author":"Kitzman","year":"2014","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jchf.2018.01.009_bib25","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.amjcard.2013.12.031","article-title":"Skeletal muscle composition and its relation to exercise intolerance in older patients with heart failure and preserved ejection fraction","volume":"113","author":"Haykowsky","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2018.01.009_bib26","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/gerona\/glt011","article-title":"Impaired aerobic capacity and physical functional performance in older heart failure patients with preserved ejection fraction: role of lean body mass","volume":"68","author":"Haykowsky","year":"2013","journal-title":"J\u00a0Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.jchf.2018.01.009_bib27","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jacc.2016.05.043","article-title":"High-output heart failure: a 15-year experience","volume":"68","author":"Reddy","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2018.01.009_bib28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijcard.2017.01.130","article-title":"BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: the Atherosclerosis Risk in Communities Surveillance Study","volume":"233","author":"Khalid","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jchf.2018.01.009_bib29","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.jacl.2017.08.018","article-title":"Evolutional change in epicardial fat and its correlation with myocardial diffuse fibrosis in heart failure patients","volume":"11","author":"Wu","year":"2017","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jchf.2018.01.009_bib30","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1001\/jamacardio.2017.2511","article-title":"Temporal relation between myocardial fibrosis and heart failure with preserved ejection fraction: association with baseline disease severity and subsequent outcome","volume":"2","author":"Schelbert","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"4","key":"10.1016\/j.jchf.2018.01.009_bib31","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003612","article-title":"Percutaneous pericardial resection: a novel potential treatment for heart failure with preserved ejection fraction","volume":"10","author":"Borlaug","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2018.01.009_bib32","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/ijo.2010.227","article-title":"Neprilysin, obesity and the metabolic syndrome","volume":"35","author":"Standeven","year":"2011","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.jchf.2018.01.009_bib33","doi-asserted-by":"crossref","first-page":"R104","DOI":"10.1152\/ajpregu.00499.2015","article-title":"Insulin\/glucose induces natriuretic peptide clearance receptor in human adipocytes: a metabolic link with the cardiac natriuretic pathway","volume":"311","author":"Bordicchia","year":"2016","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.jchf.2018.01.009_bib34","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.0000112582.16683.EA","article-title":"Impact of obesity on plasma natriuretic peptide levels","volume":"109","author":"Wang","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2018.01.009_bib35","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1210\/js.2017-00020","article-title":"Effects of rapid weight loss on systemic and adipose tissue inflammation and metabolism in obese postmenopausal women","volume":"1","author":"Alem\u00e1n","year":"2017","journal-title":"J\u00a0Endocr Soc"},{"key":"10.1016\/j.jchf.2018.01.009_bib36","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jcjd.2016.12.003","article-title":"Impact of bariatric surgery on white adipose tissue inflammation","volume":"41","author":"Labrecque","year":"2017","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.jchf.2018.01.009_bib37","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA.116.025629","article-title":"Weight loss and heart failure: a nationwide study of gastric bypass surgery versus intensive lifestyle treatment","volume":"135","author":"Sundstr\u00f6m","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2018.01.009_bib38","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/jama.2015.17346","article-title":"Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial","volume":"315","author":"Kitzman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2018.01.009_bib39","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.cardfail.2012.09.005","article-title":"Obesity and the response to intensified diuretic treatment in decompensated heart failure: a DOSE trial substudy","volume":"18","author":"Gupta","year":"2012","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jchf.2018.01.009_bib40","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1210\/jc.2007-1088","article-title":"Body mass index predicts aldosterone production in normotensive adults on a high-salt diet","volume":"92","author":"Bentley-Lewis","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jchf.2018.01.009_bib41","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2174\/187153011796429853","article-title":"The role of angiotensin in obesity and metabolic disease","volume":"11","author":"Mathai","year":"2011","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"10.1016\/j.jchf.2018.01.009_bib42","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1161\/CIRCULATIONAHA.115.018226","article-title":"Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis","volume":"132","author":"Huby","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2018.01.009_bib43","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.190223","article-title":"Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction","volume":"59","author":"Briones","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.jchf.2018.01.009_bib44","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3109\/10641963.2014.987391","article-title":"Comparison of aldosterone synthesis in adrenal cells, effect of various AT1 receptor blockers with or without atrial natriuretic peptide","volume":"37","author":"Miura","year":"2015","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.jchf.2018.01.009_bib45","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1055\/s-0035-1559769","article-title":"Epicardial fat thickness and primary aldosteronism","volume":"48","author":"Iacobellis","year":"2016","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.jchf.2018.01.009_bib46","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1055\/s-2005-870240","article-title":"Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes","volume":"37","author":"Kraus","year":"2005","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.jchf.2018.01.009_bib47","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1515\/hmbci-2014-0013","article-title":"Crosstalk between adipose tissue and blood vessels in cardiometabolic syndrome: implication of steroid hormone receptors (MR\/GR)","volume":"19","author":"Even","year":"2014","journal-title":"Horm Mol Biol Clin Investig"},{"key":"10.1016\/j.jchf.2018.01.009_bib48","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bbrc.2012.01.139","article-title":"Contribution of glucocorticoid-mineralocorticoid receptor pathway on the obesity-related adipocyte dysfunction","volume":"419","author":"Hirata","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jchf.2018.01.009_bib49","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jash.2014.04.008","article-title":"Accumulation of microvascular target organ damage in newly diagnosed hypertensive patients","volume":"8","author":"Triantafyllou","year":"2014","journal-title":"J\u00a0Am Soc Hypertens"},{"key":"10.1016\/j.jchf.2018.01.009_bib50","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jchf.2018.01.009_bib51","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1111\/bph.13479","article-title":"Preventive and chronic mineralocorticoid receptor antagonism is highly beneficial in obese SHHF rats","volume":"173","author":"Youcef","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jchf.2018.01.009_bib52","doi-asserted-by":"crossref","first-page":"H1126","DOI":"10.1152\/ajpheart.00898.2014","article-title":"Mineralocorticoid receptor blockade prevents Western diet-induced diastolic dysfunction in female mice","volume":"308","author":"Bostick","year":"2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jchf.2018.01.009_bib53","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1161\/HYPERTENSIONAHA.114.04912","article-title":"Mineralocorticoid receptor antagonism treats obesity-associated cardiac diastolic dysfunction","volume":"65","author":"Bender","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.jchf.2018.01.009_bib54","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/1475-2840-12-172","article-title":"Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes","volume":"12","author":"Ram\u00edrez","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jchf.2018.01.009_bib55","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jacc.2016.07.763","article-title":"Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction","volume":"68","author":"Kosmala","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2018.01.009_bib56","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2018.01.009_bib57","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.cardfail.2011.04.007","article-title":"Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF)","volume":"17","author":"Deswal","year":"2011","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jchf.2018.01.009_bib58","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/heartjnl-2012-303329","article-title":"Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade","volume":"99","author":"Kosmala","year":"2013","journal-title":"Heart"},{"key":"10.1016\/j.jchf.2018.01.009_bib59","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/CIRCHEARTFAILURE.111.962654","article-title":"Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial","volume":"4","author":"Anand","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2018.01.009_bib60","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2018.01.009_bib61","first-page":"241","article-title":"Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial","volume":"5","author":"Anand","year":"2017","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2018.01.009_bib62","doi-asserted-by":"crossref","first-page":"48066","DOI":"10.1074\/jbc.M204058200","article-title":"Human adipose tissue cells keep tight control on the angiotensin II levels in their vicinity","volume":"277","author":"Schling","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jchf.2018.01.009_bib63","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1161\/CIRCRESAHA.116.305697","article-title":"Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms","volume":"116","author":"Hall","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.jchf.2018.01.009_bib64","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/j.jacc.2017.08.056","article-title":"Renal sympathetic denervation protects the failing heart via inhibition of neprilysin activity in the kidney","volume":"70","author":"Polhemus","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2018.01.009_bib65","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1161\/CIRCHEARTFAILURE.113.000885","article-title":"Atrial natriuretic peptide locally counteracts the deleterious effects of cardiomyocyte mineralocorticoid receptor activation","volume":"7","author":"Nakagawa","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2018.01.009_bib66","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1073\/pnas.070371497","article-title":"Cardiac fibrosis in mice lacking brain natriuretic peptide","volume":"97","author":"Tamura","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jchf.2018.01.009_bib67","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jacc.2011.05.042","article-title":"Lipolytic effects of B-type natriuretic peptide 1-32 in adipose tissue of heart failure patients compared with healthy controls","volume":"58","author":"Polak","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2018.01.009_bib68","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/ijo.2015.222","article-title":"Impaired atrial natriuretic peptide-mediated lipolysis in obesity","volume":"40","author":"Ryd\u00e9n","year":"2016","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.jchf.2018.01.009_bib69","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1016\/j.ijcard.2013.03.015","article-title":"High concentration of C-type natriuretic peptide promotes VEGF-dependent vasculogenesis in the remodeled region of infarcted swine heart with preserved left ventricular ejection fraction","volume":"168","author":"Del Ry","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jchf.2018.01.009_bib70","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1161\/CIRCULATIONAHA.117.030418","article-title":"Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure","volume":"136","author":"Packer","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2018.01.009_bib71","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular out-comes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2018.01.009_bib72","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/dom.13126","article-title":"Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis","volume":"20","author":"Hallow","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jchf.2018.01.009_bib73","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13098-017-0275-4","article-title":"Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus","volume":"9","author":"Yagi","year":"2017","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.jchf.2018.01.009_bib74","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12933-016-0473-7","article-title":"Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome","volume":"15","author":"Kusaka","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jchf.2018.01.009_bib75","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10557-017-6725-2","article-title":"SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3\/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor","volume":"31","author":"Ye","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jchf.2018.01.009_bib76","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12933-016-0489-z","article-title":"Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes","volume":"16","author":"Habibi","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jchf.2018.01.009_bib77","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1161\/CIRCULATIONAHA.117.032474","article-title":"The leptin-aldosterone-neprilysin axis: identification of its role in the pathogenesis of the three phenotypes of heart failure in obese people","volume":"137","author":"Packer","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2018.01.009_bib78","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1042\/CS20160803","article-title":"GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction","volume":"131","author":"Pastel","year":"2017","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.jchf.2018.01.009_bib79","doi-asserted-by":"crossref","first-page":"742","DOI":"10.2337\/db15-1224","article-title":"Inhibition of dipeptidyl peptidase-4 impairs ventricular function and promotes cardiac fibrosis in high fat-fed diabetic mice","volume":"65","author":"Mulvihill","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.jchf.2018.01.009_bib80","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","article-title":"Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice","volume":"13","author":"Lin","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jchf.2018.01.009_bib81","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12933-017-0510-1","article-title":"A\u00a0randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation","volume":"16","author":"Ott","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jchf.2018.01.009_bib82","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2018.01.009_bib83","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2018.01.009_bib84","unstructured":"US Food and Drug Administration. Diabetes medications containing saxagliptin and alogliptin: drug safety communication - risk of heart failure. April 5, 2016. Available at: https:\/\/www.fda.gov\/safety\/medwatch\/safetyinformation\/safetyalertsforhumanmedicalproducts\/ucm494252.htm. Accessed January 29,\u00a02018."},{"key":"10.1016\/j.jchf.2018.01.009_bib85","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/ejhf.1047","article-title":"Will long-acting glucagon-like peptide-1 analogues recapitulate our agonizing experience with cyclic AMP-dependent positive inotropic agents in heart failure?","volume":"20","author":"Packer","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2018.01.009_bib86","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2018.01.009_bib87","first-page":"471","article-title":"Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial","volume":"5","author":"Solomon","year":"2017","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2018.01.009_bib88","unstructured":"Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction (EMPEROR-Preserved). ClinicalTrials.gov Identifier: NCT03057951. Available at: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=NCT03057951&cntry=&state=&city=&dist=. Accessed January 29,\u00a02018."}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177918300623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177918300623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T17:30:30Z","timestamp":1719855030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177918300623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":88,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S2213177918300623"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2018.01.009","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obesity-Related Heart Failure With a Preserved Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2018.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}